Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $152.00 Price Target at Citizens Jmp

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective trimmed by Citizens Jmp from $176.00 to $152.00 in a report released on Tuesday,Benzinga reports. The firm currently has a market outperform rating on the stock.

A number of other brokerages have also recently issued reports on RYTM. Needham & Company LLC lowered their price objective on Rhythm Pharmaceuticals from $139.00 to $130.00 and set a “buy” rating on the stock in a research note on Tuesday. Stifel Nicolaus set a $131.00 target price on shares of Rhythm Pharmaceuticals in a research note on Thursday, February 26th. Wells Fargo & Company boosted their price target on shares of Rhythm Pharmaceuticals from $136.00 to $143.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Citigroup reiterated an “outperform” rating on shares of Rhythm Pharmaceuticals in a research note on Friday, December 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Rhythm Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $131.75.

Rhythm Pharmaceuticals Trading Down 3.1%

Shares of NASDAQ RYTM opened at $87.68 on Tuesday. The stock has a fifty day simple moving average of $99.77 and a two-hundred day simple moving average of $102.81. Rhythm Pharmaceuticals has a 1-year low of $45.90 and a 1-year high of $122.20. The firm has a market cap of $5.99 billion, a price-to-earnings ratio of -28.19 and a beta of 2.06.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.The firm had revenue of $57.25 million for the quarter, compared to analyst estimates of $56.16 million. During the same period in the previous year, the company posted ($0.72) earnings per share. The business’s revenue was up 36.9% on a year-over-year basis. Analysts forecast that Rhythm Pharmaceuticals will post -4.32 EPS for the current year.

Insider Activity at Rhythm Pharmaceuticals

In other news, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the transaction, the chief financial officer owned 110,512 shares of the company’s stock, valued at approximately $11,190,445.12. This represents a 3.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Christopher Paul German sold 5,614 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total value of $502,789.84. Following the completion of the sale, the chief accounting officer owned 160 shares in the company, valued at $14,329.60. This trade represents a 97.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 27,267 shares of company stock valued at $2,719,955. 6.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Xponance LLC raised its holdings in shares of Rhythm Pharmaceuticals by 2.6% in the 4th quarter. Xponance LLC now owns 4,269 shares of the company’s stock valued at $457,000 after acquiring an additional 107 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Rhythm Pharmaceuticals by 4.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,568 shares of the company’s stock worth $259,000 after purchasing an additional 110 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Rhythm Pharmaceuticals by 39.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 399 shares of the company’s stock valued at $43,000 after purchasing an additional 113 shares in the last quarter. Captrust Financial Advisors raised its stake in Rhythm Pharmaceuticals by 0.7% in the second quarter. Captrust Financial Advisors now owns 17,471 shares of the company’s stock valued at $1,104,000 after purchasing an additional 114 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Rhythm Pharmaceuticals by 48.6% during the fourth quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock valued at $39,000 after purchasing an additional 118 shares during the last quarter.

Rhythm Pharmaceuticals News Summary

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Company delivered solid revenue growth and a Q4 beat (FY25 revenue $194.8M, +50% year/year), which supports continued commercial demand for IMCIVREE (setmelanotide) and underpins longer-term upside. Article Title
• Positive Sentiment: Company highlights post‑hoc analyses showing statistically significant BMI reductions at 52 weeks in patients with heterozygous POMC/PCSK1 and SRC1 (NCOA1) variants — these subgroup signals could support label expansion or targeted use, which investors may view as constructive if regulators/market accept the evidence. Article Title
• Neutral Sentiment: Company-hosted transcript and slide materials on the EMANATE topline results are available for investors evaluating the detailed data and management commentary; these provide context for both the misses and the subgroup findings. Transcript Slides
• Negative Sentiment: Topline EMANATE results showed the experimental obesity program did not meet several pre‑specified primary endpoints across four substudies — the primary failure is the main driver of near‑term negative sentiment and regulatory scrutiny. Reuters
• Negative Sentiment: Multiple major brokerages trimmed price targets today (Citigroup, RBC, Citizens JMP, BofA, Morgan Stanley, Needham). Although most retained buy/outperform ratings, the lower targets signal reduced near‑term upside expectations and likely contributed to selling pressure. Benzinga TickerReport

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.